Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Receivables (2023 - 2025)

Connect Biopharma Holdings' Receivables history spans 3 years, with the latest figure at $174000.0 for Q3 2025.

  • For Q3 2025, Receivables changed N/A year-over-year to $174000.0; the TTM value through Sep 2025 reached $174000.0, changed N/A, while the annual FY2024 figure was $1.1 million, 199.43% up from the prior year.
  • Receivables for Q3 2025 was $174000.0 at Connect Biopharma Holdings, down from $193000.0 in the prior quarter.
  • Across five years, Receivables topped out at $1.1 million in Q4 2024 and bottomed at $174000.0 in Q3 2025.
  • The 3-year median for Receivables is $193000.0 (2025), against an average of $388800.0.
  • The largest YoY upside for Receivables was 199.43% in 2024 against a maximum downside of 199.43% in 2024.
  • A 3-year view of Receivables shows it stood at $351000.0 in 2023, then skyrocketed by 199.43% to $1.1 million in 2024, then plummeted by 83.44% to $174000.0 in 2025.
  • Per Business Quant, the three most recent readings for CNTB's Receivables are $174000.0 (Q3 2025), $193000.0 (Q2 2025), and $175000.0 (Q1 2025).